Why Is VERADERMICS INC (MANE) Stock Moving Today?

Veradermics Inc (MANE) shares surged 8.09% to $114.41 in a volatile session driven by positive developments in the company’s clinical trials for hair-loss treatments. The stock opened with a 4.9% gap up and reached an intraday high of $116.75 before consolidating gains. The rise follows the release of data from a subgroup analysis of its Phase 2/3 trial for VDPHL01, which showed early results in both male and female participants.

What Happened

Veradermics announced the presentation of data from a subgroup analysis of its Phase 2/3 Study 302, which evaluated VDPHL01 in males with pattern hair loss. The study is part of a broader clinical program for the extended-release oral minoxidil treatment. Separately, data from a Phase 2 trial of VDPHL01 in female subjects showed an increase in hair count as early as the second month of treatment. These developments have generated optimism about the drug’s potential in both male and female hair-loss markets. The company is also funded through 2030, providing visibility for continued development. Citigroup and Needham recently raised their price targets for MANE to $160 and $164 respectively, maintaining Buy ratings.

What The Data Shows

MANE opened at $111.00, a 4.9% gap up from the prior close, and traded as high as $116.75 before settling at $114.18. The session saw a low of $105.01, reflecting early volatility. Trading volume reached 0.2 million shares, which is 0.3 times the 3-month average. The stock is currently trading within its 52-week range of $32.00 to $131.24. Despite a market cap of $4.6 billion, the company remains unprofitable, with an EPS of -15.84 for the trailing twelve months.

What To Watch

Veradermics is expected to report top-line results from Study 304 in the second half of 2026. Investors will also monitor the breadth of analyst coverage and any further updates on clinical trial progress.